Colin Thomas
Overview
Explore the profile of Colin Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grover N, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzman A, et al.
Blood Cancer J
. 2024 Oct;
14(1):182.
PMID: 39424808
Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of large B cells (LC). However, there...
2.
Matsumura S, Signoretti C, Fatehi S, Tumenbayar B, DAddario C, Nimmer E, et al.
J Biol Chem
. 2024 Jun;
300(7):107460.
PMID: 38876306
Obesity is a major risk factor for liver and cardiovascular diseases. However, obesity-driven mechanisms that contribute to the pathogenesis of multiple organ diseases are still obscure and treatment is inadequate....
3.
Epperla N, Zhao Q, Moyo T, Watkins M, Tavakkoli M, Bello C, et al.
Blood Adv
. 2023 Dec;
8(3):549-552.
PMID: 38091577
No abstract available.
4.
Cosme M, Thomas C, Gaucherel C
Entropy (Basel)
. 2023 Nov;
25(11).
PMID: 37998218
Ecosystem modeling is a complex and multidisciplinary modeling problem which emerged in the 1950s. It takes advantage of the computational turn in sciences to better understand anthropogenic impacts and improve...
5.
Rosenberg M, Poluch M, Thomas C, Sindaco P, Khoo A, Porcu P
Front Oncol
. 2023 Nov;
13:1275800.
PMID: 37927464
Nearly a billion people worldwide are infected with the hepatitis B Virus (HBV) and about a third of them have chronic infection. HBV is an important cause of morbidity and...
6.
Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh T, et al.
Blood Adv
. 2023 Jun;
7(17):5038-5046.
PMID: 37315169
Given the paucity of data surrounding the prognostic relevance of monoclonal paraprotein (M-protein) in marginal zone lymphoma (MZL), we sought to evaluate the impact of detecting M-protein at diagnosis on...
7.
Epperla N, Welkie R, Torka P, Shouse G, Karmali R, Shea L, et al.
J Hematol Oncol
. 2023 May;
16(1):49.
PMID: 37158890
Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not...
8.
Thomas C, Thapa S, McLaughlin C, Halloran M, Porcu P
Front Oncol
. 2023 Jan;
12:1098375.
PMID: 36686842
No abstract available.
9.
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, et al.
Blood Adv
. 2022 Oct;
7(1):88-91.
PMID: 36269847
No abstract available.
10.
Epperla N, Zhao Q, Chowdhury S, Shea L, Moyo T, Reddy N, et al.
J Hematol Oncol
. 2022 Jul;
15(1):96.
PMID: 35842643
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to...